Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine and Melphalan vs Melphalan for ASCT in Myeloma
NCT03187223Phase 2Completed
- Sponsor
- Insel Gruppe
- Start
- Jul 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bendamustine in multiple myeloma (MM) (2 arms), sponsored by Insel Gruppe. Primary endpoint: Complete Remission Rate at 60 days. Started Jul 2017; status: completed.
02
Drugs
bendamustine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03187223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03187223.